A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone

NCT01142466 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: Interferon beta-1a (Rebif)

Sponsor

Merck KGaA, Darmstadt, Germany

Collaborators

[object Object]